An Integrative Multimodal Model for Early Diagnosis of Dementia and Differential Diagnosis of Alzheimer's Disease Using Neuroimaging, Polygenic Risk, and Cognitive Assessments
Filiz, T. T.; Fominykh, V.; Persson, K.; Michelet, M.; Broce, I. J.; Medboen, I. T.; Aam, S.; Shadrin, A.; Alnaes, D.; Athanasiu, L.; Wang, X.; Sanda, G.; Saltvedt, I. T.; Knapskog, A.-B.; Selbaek, G.; Dale, A. M.; Andreassen, O. A.; Frei, O.
Show abstract
Background: Early diagnosis and etiological classification of dementia remain challenging, as clinicians typically lack tools to integrate cognitive, neuroimaging, and genetic data quantitatively. We developed and validated multimodal risk models to support early diagnosis of dementia and differential diagnosis of Alzheimer's disease (AD) versus non-AD dementias in real-world clinical settings and translated model outputs into individualized risk reports. Methods: Utilizing real-world clinical cohorts (n = 1,100 for early diagnosis of dementia, using clinical diagnoses up to three years after clinical assessment; n = 788 for AD differential diagnosis) from Norwegian Memory Clinics, we trained and validated the Multimodal Hazard Score for Real-World Data (MHS-RWD) model integrating demographics (age, sex), cognitive assessments (MMSE-NR3 or CERAD 10-word delayed recall), the MRI-derived Imaging Hazard Score, and the Polygenic Hazard Score. Discrimination performance was examined using the area under the receiver operating characteristic curve (AUC). Results: In real-world clinical data, the MHS-RWD consistently outperformed any single predictor used alone. For early diagnosis of dementia, the full model achieved an AUC of 0.89 in females and 0.84 in males. For the differential diagnosis of AD from other dementias, the multimodal model yielded an AUC of 0.91 in females and 0.83 in males. A patient-level risk report was designed to present individualized risk estimates. Conclusions: Multimodal integration of cognitive, neuroimaging, and polygenic data in the MHS-RWD tool yields strong discrimination for both early diagnosis of dementia and AD differential diagnosis. The tool relies on data obtainable in clinical care, and genetic information that is becoming increasingly available in routine practice. Delivered through intuitive patient-level risk reports, it could support etiologically informed dementia decisions in real-world settings, with potential utility in primary care.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Continuous Associations Between Remote Self-Administered Cognitive Measures and Imaging Biomarkers of Alzheimer’s Disease 94%
- Longitudinal subcortical volume changes and their correlations with multiple PET and fluid biomarkers in dominantly inherited Alzheimer disease. 94%
- A conformational variant of p53 (U-p53 AZ ) as blood-based biomarker for the prediction of the onset of symptomatic Alzheimer’s disease 93%
Similar papers in this journal
- Investigating the Amyloid-Tau-Neurodegeneration Framework in Alzheimer's Disease Using Semi-Supervised Multimodal Imaging Data Fusion 96%
- Evaluation of a speech-based AI system for early detection of Alzheimer’s disease remotely via smartphones 95%
- Discovering Subtypes with Imaging Signatures in the Motoric Cognitive Risk Syndrome Consortium using Weakly-Supervised Clustering 94%
Similar papers in this journal
- A metabolite-based machine learning approach to diagnose Alzheimer's-type dementia in blood: Results from the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort 95%
- The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: longitudinal findings from the Catch-Cog study cohort 94%
- LD-informed deep learning for Alzheimer’s gene loci detection using WGS data 92%
Similar papers in this journal
- Examining a Preclinical Alzheimer’s Cognitive Composite for Telehealth Administration, the tPACC, for Reliability between In-Person and Remote Cognitive Testing with Neuroimaging Biomarkers 95%
- Risk models based on non-cognitive measures may identify presymptomatic Alzheimer’s disease 95%
- Screening for early-stage Alzheimer's disease using optimized feature sets and machine learning 94%